Table 1. Clinical characteristics of the 97 patients (with 137 brain metastases) treated with RS for brain metastases.
| Clinical characteristics | Patients who received SRS n=56 | Patients who received hFSRT n=41 |
|---|---|---|
| Age (y) | ||
| Median | 63 | 64 |
| Range | 32-87 | 32-89 |
| Gender (female/male) | 24/32 | 21/20 |
| Histology | ||
| NSCLC | 43 | 23 |
| Breast | 5 | 9 |
| Melanoma | 1 | 0 |
| RCC | 1 | 3 |
| GI | 3 | 1 |
| Other | 3 | 5 |
| KPS | ||
| 70-100 | 42 | 29 |
| <70 | 14 | 12 |
| Extracranial disease | ||
| Present | 31 | 28 |
| Absent | 25 | 13 |
| Number of metastases | ||
| 1 | 35 | 30 |
| 2 | 14 | 5 |
| 3 | 3 | 3 |
| ≥4 | 4 | 3 |
| Previous WBRT | ||
| Yes | 26 | 12 |
| No | 30 | 29 |
SRS: Stereotactic radiosurgery, hFSRT: Hypofractionated stereotactic radiotherapy, NSCLC: Non-small cell lung cancer, KPS: Karfsnosky Performance Status, WBRT: Wholebrain radiotherapy, RCC: Renal cell carcinoma, GI: Gastrointestinal